These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35464395)

  • 1. The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies.
    Becker JP; Riemer AB
    Front Immunol; 2022; 13():883989. PubMed ID: 35464395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
    Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
    Front Immunol; 2018; 9():912. PubMed ID: 29780384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do cancer-specific CD8+ T cells see? The contribution of immunopeptidomics.
    Nicholas B; Skipp P
    Essays Biochem; 2023 Sep; 67(6):957-965. PubMed ID: 37503576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.
    Chikata T; Paes W; Akahoshi T; Partridge T; Murakoshi H; Gatanaga H; Ternette N; Oka S; Borrow P; Takiguchi M
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31217245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
    ElAbd H; Franke A
    Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.
    ElAbd H; Bacher P; Tholey A; Lenz TL; Franke A
    Front Immunol; 2023; 14():1107266. PubMed ID: 37063883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells.
    Weisbrod L; Capriotti L; Hofmann M; Spieler V; Dersch H; Voedisch B; Schmidt P; Knake S
    Front Immunol; 2024; 15():1386160. PubMed ID: 38779658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
    Minegishi Y; Haga Y; Ueda K
    Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Targeted LC-MS Strategy for Low-Abundant HLA Class-I-Presented Peptide Detection Identifies Novel Human Papillomavirus T-Cell Epitopes.
    Blatnik R; Mohan N; Bonsack M; Falkenby LG; Hoppe S; Josef K; Steinbach A; Becker S; Nadler WM; Rucevic M; Larsen MR; Salek M; Riemer AB
    Proteomics; 2018 Jun; 18(11):e1700390. PubMed ID: 29603667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOF
    Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
    Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
    Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing.
    Pan Y; Phillips JW; Zhang BD; Noguchi M; Kutschera E; McLaughlin J; Nesterenko PA; Mao Z; Bangayan NJ; Wang R; Tran W; Yang HT; Wang Y; Xu Y; Obusan MB; Cheng D; Lee AH; Kadash-Edmondson KE; Champhekar A; Puig-Saus C; Ribas A; Prins RM; Seet CS; Crooks GM; Witte ON; Xing Y
    Proc Natl Acad Sci U S A; 2023 May; 120(21):e2221116120. PubMed ID: 37192158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material.
    Salek M; Förster JD; Becker JP; Meyer M; Charoentong P; Lyu Y; Lindner K; Lotsch C; Volkmar M; Momburg F; Poschke I; Fröhling S; Schmitz M; Offringa R; Platten M; Jäger D; Zörnig I; Riemer AB
    Mol Cell Proteomics; 2024 Sep; 23(9):100825. PubMed ID: 39111711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
    Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
    Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
    Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.
    de Beijer MTA; Jansen DTSL; Dou Y; van Esch WJE; Mok JY; Maas MJP; Brasser G; de Man RA; Woltman AM; Buschow SI
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31852786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.